Drug
CPC-201
CPC-201 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
NCT02185053
completedphase_2
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02434666
withdrawnphase_2
CPC-201 Alzheimer's Disease Type Dementia: PET Study
NCT02860065
Clinical Trials (3)
Showing 3 of 3 trials
NCT02185053Phase 2
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
NCT02434666Phase 2
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02860065Phase 2
CPC-201 Alzheimer's Disease Type Dementia: PET Study
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3